Arcus Biosciences (RCUS) Stock Price, News & Analysis

Company Overview

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody. Additional pipeline assets explore dual checkpoint blockade and next-generation immune modulators. Arcus conducts multi-center clinical trials across North America, Europe and Asia, collaborating with academic institutions and global partners to advance its oncology portfolio.

Founded in 2015 and headquartered in Redwood City, California, Arcus completed its initial public offering on the New York Stock Exchange in June 2020 under the ticker RCUS. The company has since forged strategic alliances with leading biopharmaceutical firms to accelerate clinical development and broaden the potential application of its immuno-oncology therapeutics.

Arcus is led by President and Chief Executive Officer Terry Rosen, who co-founded the company and brings extensive experience in biotech leadership and oncology drug development. The senior management team combines expertise in translational medicine, clinical operations and commercial strategy to guide Arcus toward its goal of delivering new treatment options for patients with cancer.

Key Stats

• Today's Range: $23.80 to $24.84
• 50-Day Range: $22.25 to $26.69
• 52-Week Range: $7.91 to $28.72
• Volume: 2.31 million shs
• Average Volume: 1.04 million shs
• Market Capitalization: $3.07 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.10
• Consensus Rating: Moderate Buy

Arcus Biosciences Stock Analysis - MarketRank™

Arcus Biosciences scored higher than 62% of companies evaluated by MarketBeat, and ranked 256th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on no strong buy ratings, 8 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Arcus Biosciences has a consensus price target of $35.10, representing about 43.9% upside from its current price of $24.39.

Amount of Analyst Coverage

Arcus Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arcus Biosciences are expected to grow in the coming year, from ($3.66) to ($3.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcus Biosciences is -7.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcus Biosciences is -7.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcus Biosciences has a P/B Ratio of 4.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.30% of the float of Arcus Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Arcus Biosciences has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Arcus Biosciences has recently increased by 7.55%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcus Biosciences does not currently pay a dividend.

Dividend Growth

Arcus Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.29

News Sentiment

Arcus Biosciences has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Arcus Biosciences this week, compared to 5 articles on an average week.

Search Interest

1 people have searched for RCUS on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arcus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $264,988.00 in company stock.

Percentage Held by Insiders

9.60% of the stock of Arcus Biosciences is held by insiders.

Percentage Held by Institutions

92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 6/19/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:RCUS
• CIK: 1724521
• Web: www.arcusbio.com
• Phone: (510) 694-6200
• Fax: N/A
• Employees: 500
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Arcus Biosciences: $35.10
• High Price Target: $47.00
• Low Price Target: $22.00
• Potential Upside/Downside: +43.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.58
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$353 million
• Net Margins: -156.36%
• Pretax Margin: -156.36%
• Return on Equity: -68.97%
• Return on Assets: -35.27%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 4.04
• Quick Ratio: 4.04

Sales & Book Value

• Annual Sales: $247 million
• Price / Sales: 12.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.84 per share
• Price / Book: 4.18

Miscellaneous

• Outstanding Shares: 125,770,000
• Free Float: 113,699,000
• Market Cap: $3.07 billion
• Optionable: Optionable
• Beta: 0.85